E, C., M, M., E, H., J, M., A, R., F, F., . . . C, C. (2025). Impact of nirsevimab immunoprophylaxis on respiratory syncytial virus-related outcomes in hospital and primary care after two consecutive seasons: A population-based retrospective cohort study in infants in their second year of life in Catalonia, Spain. European journal of pediatrics, 184(10), 616. https://doi.org/10.1007/s00431-025-06440-x
Chicago Style (17th ed.) CitationE, Coma, et al. "Impact of Nirsevimab Immunoprophylaxis on Respiratory Syncytial Virus-related Outcomes in Hospital and Primary Care After Two Consecutive Seasons: A Population-based Retrospective Cohort Study in Infants in Their Second Year of Life in Catalonia, Spain." European Journal of Pediatrics 184, no. 10 (2025): 616. https://doi.org/10.1007/s00431-025-06440-x.
MLA (9th ed.) CitationE, Coma, et al. "Impact of Nirsevimab Immunoprophylaxis on Respiratory Syncytial Virus-related Outcomes in Hospital and Primary Care After Two Consecutive Seasons: A Population-based Retrospective Cohort Study in Infants in Their Second Year of Life in Catalonia, Spain." European Journal of Pediatrics, vol. 184, no. 10, 2025, p. 616, https://doi.org/10.1007/s00431-025-06440-x.
